Capricor Therapeutics Inc
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Capricor Therapeutics' stock with a target price of $25.5, indicating strong growth potential.
Financial Health
Capricor Therapeutics is generating solid revenue and cash flow, demonstrating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CAPR
Gene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketDavid Vs. Goliath
This carefully curated selection features ambitious companies challenging industry giants with innovative strategies. Our experts have identified these potential disruptors that leverage cutting-edge technology and smarter business models to take on established market leaders.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
Progress hinges on trial readouts and regulatory milestones, which can create sharp share-price moves; outcomes are uncertain and timelines can be long.
Rare disease potential
Targeting cardiac and neuromuscular conditions can offer significant unmet-need opportunities, though commercial success depends on safety, efficacy and reimbursement paths.
High-risk profile
Small market cap and development-stage status mean higher volatility and funding sensitivity — suitable mainly for investors who tolerate elevated risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
